company background image
SLNC.F logo

Silence Therapeutics OTCPK:SLNC.F Stock Report

Last Price

US$5.50

Market Cap

US$827.4m

7D

-5.3%

1Y

504.5%

Updated

04 Nov, 2024

Data

Company Financials +

Silence Therapeutics plc

OTCPK:SLNC.F Stock Report

Market Cap: US$827.4m

SLNC.F Stock Overview

A biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

SLNC.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Silence Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUS$5.50
52 Week HighUS$14.75
52 Week LowUS$1.50
Beta1.28
11 Month Change-11.29%
3 Month Change-8.33%
1 Year Change504.46%
33 Year Change-23.21%
5 Year Change12.70%
Change since IPO316.67%

Recent News & Updates

Recent updates

Shareholder Returns

SLNC.FUS BiotechsUS Market
7D-5.3%-0.7%-1.6%
1Y504.5%19.8%30.8%

Return vs Industry: SLNC.F exceeded the US Biotechs industry which returned 19.8% over the past year.

Return vs Market: SLNC.F exceeded the US Market which returned 30.8% over the past year.

Price Volatility

Is SLNC.F's price volatile compared to industry and market?
SLNC.F volatility
SLNC.F Average Weekly Movement22.4%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: SLNC.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SLNC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994109Craig Toomanwww.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.

Silence Therapeutics plc Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLNC.F fundamental statistics
Market capUS$827.39m
Earnings (TTM)-US$51.81m
Revenue (TTM)US$23.13m

35.8x

P/S Ratio

-16.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLNC.F income statement (TTM)
RevenueUK£17.90m
Cost of RevenueUK£7.80m
Gross ProfitUK£10.10m
Other ExpensesUK£50.20m
Earnings-UK£40.10m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.86
Gross Margin56.40%
Net Profit Margin-224.01%
Debt/Equity Ratio0%

How did SLNC.F perform over the long term?

See historical performance and comparison